- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07900607
The Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants
An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]OD-001 in Healthy Male Participants
This study looks at how the body handles an investigational drug called OD-001. Researchers want to learn how the medicine is absorbed, how it is broken down, and how it leaves the body.
About 8 healthy men will join the study, so that at least 6 people complete it. Each participant will drink a single dose of OD-001 as a liquid. This will be done on an empty stomach, so each participant will be asked not to eat for a period of time beforehand.
The medicine contains a small amount of a radioactive "tracer" (carbon-14). The tracer lets researchers follow the medicine and its breakdown products through your body. The amount of radioactivity is small and carefully limited. After the dose, researchers will collect samples such as blood, urine and stool. These will show how much of the medicine is recovered and what it turns into in the body.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Kelly Bourdon
- Numéro de téléphone: 857-393-6160
- E-mail: clinicaltrials@odysseytx.com
Lieux d'étude
-
-
-
Ruddington, Royaume-Uni
- Recrutement
- Quotient Sciences
-
Contact:
- Study Coordinator
- Numéro de téléphone: +44 (0)115 974 9000
- E-mail: clinicaltrials@odysseytx.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Aged 30 to 65 years inclusive at the time of signing informed consent
- Must agree to adhere to the contraception requirements. In addition, vasectomised male participants with partners of childbearing potential must have received medical assessment of the surgical success of the procedure Healthy male participants according to the assessment of the Investigator, as based on a complete medical history including a physical examination, vital signs, single 12-lead ECGs, and laboratory safety tests without any clinically significant abnormalities as measured at screening. ECGs and vital signs to be re-checked at pre-dose.
- Body mass index (BMI) of 18.0 to 35.0 kg/m2 as measured at screening.
- Must have regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day).
Exclusion Criteria:
- Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator. Hay fever is allowed unless it is active.
- History of clinically significant cardiovascular, renal, hepatic, dermatological, respiratory, particularly GI disease, especially peptic ulceration, clinically significant GI bleeding, UC, CD, Irritable Bowel Syndrome or malabsorption syndrome that may impair bioavailability, and neurological or psychiatric disorder
- Participants who are unable to take oral medication.
- Acute diarrhea, constipation or vomiting in the 7 days before the predicted Day 1. If screening occurs >7 days before Day 1his criterion will be determined on Day 1. Diarrhoea will be defined as the passage of liquid faeces and/or a stool frequency of greater than three times per day. Constipation will be defined as a failure to open the bowels more frequently than every other day
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: [14C]OD-001
oral solution |
[14C]OD-001 |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Mass balance recovery of total radioactivity in all excreta: CumAe
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Mass balance recovery of total radioactivity in all excreta: Cum%Ae
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Number of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Identity of OD-001 metabolites at ≥10% of total exposure of [14C]-radiolabel in blood by LC-MS and NMR
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Rate of elimination of [14C]OD-001 in excreta by Ae
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Rate of elimination of [14C]OD-001 in excreta by %Ae
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Secondary Rate of elimination of [14C]OD-001 in excreta by CumAe
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Rate of elimination of [14C]OD-001 in excreta by Cum%Ae by interval
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of treatment-emergent adverse events
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Percentage of [14C] total radioactivity OD-001 metabolites in excreta
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Tmax of OD-001 in blood, total radioactivity in blood and plasma
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Cmax of OD-001 in blood, total radioactivity in blood and plasma
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
AUC0-last of OD-001 in blood, total radioactivity in blood and plasma
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
T1/2 of OD-001 in blood, total radioactivity in blood and plasma
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of abnormal clinical laboratory test results
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
|
Incidence of abnormal electrocardiograms (ECGs)
Délai: Day 1 to Day 8
|
Day 1 to Day 8
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Sharan Sidhu, MBChB, BAO, MRCS, MFPM, Quotient Sciences
- Directeur d'études: Anthony Opipari, Odyssey Therapeutics, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- OD-001-100
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .